MedMira Inc. (MMIRF)
USD 0.02
(-70.43%)
USD 0.02
(-70.43%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.65 Million CAD | -4.64% |
| 2022 | 3.82 Million CAD | -1.56% |
| 2021 | 3.89 Million CAD | 14.55% |
| 2020 | 3.39 Million CAD | 1244.88% |
| 2019 | 252.51 Thousand CAD | -16.08% |
| 2018 | 300.91 Thousand CAD | -55.33% |
| 2017 | 673.7 Thousand CAD | -22.55% |
| 2016 | 869.9 Thousand CAD | -51.23% |
| 2015 | 1.78 Million CAD | -3.16% |
| 2014 | 1.84 Million CAD | 57.86% |
| 2013 | 1.16 Million CAD | -60.72% |
| 2012 | 2.97 Million CAD | 99.06% |
| 2011 | 1.49 Million CAD | 162.62% |
| 2010 | 568.17 Thousand CAD | 8.55% |
| 2009 | 523.41 Thousand CAD | -37.18% |
| 2008 | 833.18 Thousand CAD | -70.91% |
| 2007 | 2.86 Million CAD | -28.54% |
| 2006 | 4 Million CAD | 180.64% |
| 2005 | 1.42 Million CAD | -15.67% |
| 2004 | 1.69 Million CAD | -28.26% |
| 2003 | 2.36 Million CAD | -29.8% |
| 2002 | 3.36 Million CAD | 11.05% |
| 2001 | 3.02 Million CAD | -16.26% |
| 2000 | 3.61 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 6.36 Million CAD | 42.54% |
| 2024 Q1 | 4.58 Million CAD | 25.58% |
| 2024 Q2 | 4.46 Million CAD | -2.63% |
| 2023 Q2 | 3.72 Million CAD | -1.4% |
| 2023 Q1 | 3.77 Million CAD | -1.38% |
| 2023 FY | 3.65 Million CAD | -4.64% |
| 2023 Q3 | 3.82 Million CAD | 2.81% |
| 2023 Q4 | 3.65 Million CAD | -4.62% |
| 2022 Q3 | 4.09 Million CAD | -10.01% |
| 2022 Q1 | 4.86 Million CAD | 25.15% |
| 2022 FY | 3.82 Million CAD | -1.56% |
| 2022 Q2 | 4.55 Million CAD | -6.47% |
| 2022 Q4 | 3.82 Million CAD | -6.55% |
| 2021 Q4 | 3.89 Million CAD | 5.75% |
| 2021 Q1 | 4.56 Million CAD | 34.28% |
| 2021 Q2 | 3.99 Million CAD | -12.31% |
| 2021 FY | 3.89 Million CAD | 14.55% |
| 2021 Q3 | 3.67 Million CAD | -8.01% |
| 2020 Q4 | 3.39 Million CAD | 9.61% |
| 2020 Q1 | 2.66 Million CAD | 955.27% |
| 2020 Q2 | 2.83 Million CAD | 6.29% |
| 2020 Q3 | 3.09 Million CAD | 9.4% |
| 2020 FY | 3.39 Million CAD | 1244.88% |
| 2019 Q4 | 252.51 Thousand CAD | -8.27% |
| 2019 Q1 | 289.4 Thousand CAD | -3.82% |
| 2019 FY | 252.51 Thousand CAD | -16.08% |
| 2019 Q2 | 323.75 Thousand CAD | 11.87% |
| 2019 Q3 | 275.28 Thousand CAD | -14.97% |
| 2018 Q3 | 277.39 Thousand CAD | -20.3% |
| 2018 Q4 | 300.91 Thousand CAD | 8.48% |
| 2018 FY | 300.91 Thousand CAD | -55.33% |
| 2018 Q1 | 619.21 Thousand CAD | -8.09% |
| 2018 Q2 | 348.03 Thousand CAD | -43.79% |
| 2017 Q1 | 863.24 Thousand CAD | -0.77% |
| 2017 Q4 | 673.7 Thousand CAD | -3.55% |
| 2017 Q3 | 698.53 Thousand CAD | -14.43% |
| 2017 Q2 | 816.32 Thousand CAD | -5.44% |
| 2017 FY | 673.7 Thousand CAD | -22.55% |
| 2016 FY | 869.9 Thousand CAD | -51.23% |
| 2016 Q4 | 869.9 Thousand CAD | -59.49% |
| 2016 Q1 | 4.72 Million CAD | 164.71% |
| 2016 Q3 | 2.14 Million CAD | -44.8% |
| 2016 Q2 | 3.88 Million CAD | -17.62% |
| 2015 Q4 | 1.78 Million CAD | 39.14% |
| 2015 FY | 1.78 Million CAD | -3.16% |
| 2015 Q2 | 1.23 Million CAD | -26.61% |
| 2015 Q1 | 1.68 Million CAD | -8.4% |
| 2015 Q3 | 1.28 Million CAD | 3.52% |
| 2014 FY | 1.84 Million CAD | 57.86% |
| 2014 Q4 | 1.84 Million CAD | 3.26% |
| 2014 Q3 | 1.78 Million CAD | -50.37% |
| 2014 Q2 | 3.59 Million CAD | -37.26% |
| 2014 Q1 | 5.72 Million CAD | 390.91% |
| 2013 Q1 | 2.19 Million CAD | -25.96% |
| 2013 FY | 1.16 Million CAD | -60.72% |
| 2013 Q4 | 1.16 Million CAD | 35.93% |
| 2013 Q3 | 858.38 Thousand CAD | -32.58% |
| 2013 Q2 | 1.27 Million CAD | -42.11% |
| 2012 Q3 | 591.05 Thousand CAD | -0.1% |
| 2012 Q2 | 591.66 Thousand CAD | 14.22% |
| 2012 Q1 | 517.98 Thousand CAD | -65.29% |
| 2012 FY | 2.97 Million CAD | 99.06% |
| 2012 Q4 | 2.97 Million CAD | 402.53% |
| 2011 Q3 | 517.96 Thousand CAD | -9.16% |
| 2011 Q1 | 616.38 Thousand CAD | 8.48% |
| 2011 FY | 1.49 Million CAD | 162.62% |
| 2011 Q4 | 1.49 Million CAD | 188.08% |
| 2011 Q2 | 570.18 Thousand CAD | -7.49% |
| 2010 Q1 | 490.64 Thousand CAD | -6.26% |
| 2010 Q2 | 1.2 Million CAD | 146.14% |
| 2010 Q3 | 1.03 Million CAD | -14.52% |
| 2010 Q4 | 568.17 Thousand CAD | -44.96% |
| 2010 FY | 568.17 Thousand CAD | 8.55% |
| 2009 Q3 | 690.82 Thousand CAD | -9.59% |
| 2009 FY | 523.41 Thousand CAD | -37.18% |
| 2009 Q1 | 822.25 Thousand CAD | -1.31% |
| 2009 Q2 | 764.14 Thousand CAD | -7.07% |
| 2009 Q4 | 523.41 Thousand CAD | -24.23% |
| 2008 Q4 | 833.18 Thousand CAD | -67.34% |
| 2008 FY | 833.18 Thousand CAD | -70.91% |
| 2008 Q3 | 2.55 Million CAD | -11.12% |
| 2008 Q2 | 2.86 Million CAD | 12.93% |
| 2008 Q1 | 2.54 Million CAD | -11.27% |
| 2007 Q3 | 3.72 Million CAD | -10.33% |
| 2007 FY | 2.86 Million CAD | -28.54% |
| 2007 Q2 | 4.15 Million CAD | 9.43% |
| 2007 Q4 | 2.86 Million CAD | -23.12% |
| 2007 Q1 | 3.79 Million CAD | -5.28% |
| 2006 Q3 | 4.21 Million CAD | 113.47% |
| 2006 Q4 | 4 Million CAD | -4.86% |
| 2006 FY | 4 Million CAD | 180.64% |
| 2006 Q1 | 1.73 Million CAD | 21.31% |
| 2006 Q2 | 1.97 Million CAD | 13.91% |
| 2005 Q1 | 1.61 Million CAD | -4.42% |
| 2005 FY | 1.42 Million CAD | -15.67% |
| 2005 Q3 | 1.61 Million CAD | 12.89% |
| 2005 Q4 | 1.42 Million CAD | -11.66% |
| 2005 Q2 | 1.43 Million CAD | -11.53% |
| 2004 FY | 1.69 Million CAD | -28.26% |
| 2004 Q1 | 1.59 Million CAD | -32.6% |
| 2004 Q4 | 1.69 Million CAD | 6.02% |
| 2004 Q2 | 1.54 Million CAD | -2.92% |
| 2004 Q3 | 1.59 Million CAD | 3.42% |
| 2003 Q4 | 2.36 Million CAD | 58.14% |
| 2003 FY | 2.36 Million CAD | -29.8% |
| 2003 Q1 | 2.39 Million CAD | -28.89% |
| 2003 Q2 | 2 Million CAD | -15.97% |
| 2003 Q3 | 1.49 Million CAD | -25.71% |
| 2002 Q3 | 2.68 Million CAD | -2.68% |
| 2002 FY | 3.36 Million CAD | 11.05% |
| 2002 Q4 | 3.36 Million CAD | 25.35% |
| 2002 Q1 | 2.8 Million CAD | 0.0% |
| 2002 Q2 | 2.75 Million CAD | -1.74% |
| 2001 FY | 3.02 Million CAD | -16.26% |
| 2000 FY | 3.61 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 52.7 Million USD | 93.071% |
| Skye Bioscience, Inc. | 11.94 Million USD | 69.416% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 97.195% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -561.415% |
| Qrons Inc. | 420.00 USD | -869376.667% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | 74.919% |
| CSL Limited | 38.02 Billion USD | 99.99% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 65.399% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -86.489% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -932.7% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 86.932% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -659.91% |
| Rebus Holdings, Inc. | 5000.00 USD | -72936.04% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -157986.667% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -373.864% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -431.182% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 90.6% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 49.419% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -4682.725% |
| SQZ Biotechnologies Company | 107.18 Million USD | 96.593% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -155.008% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -4946.365% |
| Mesoblast Limited | 667.9 Million USD | 99.453% |
| Marizyme, Inc. | 22.01 Million USD | 83.412% |
| Genus plc | 1.02 Billion USD | 99.645% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -168.84% |
| Pharming Group N.V. | 462.85 Million USD | 99.211% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -10.226% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -631.767% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -482.425% |
| ContraFect Corporation | 20.67 Million USD | 82.341% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -835.482% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -855.526% |
| IMV Inc. | 31.33 Million USD | 88.345% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 11.92% |
| MultiCell Technologies, Inc. | 126.22 USD | -2893103.93% |
| ONE Bio Corp. | 70.08 Million USD | 94.79% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -288.618% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 97.158% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -745.885% |
| Q BioMed Inc. | 3.51 Million USD | -3.877% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 89.619% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1297.674% |
| Biomind Labs Inc. | 73.81 Thousand USD | -4846.968% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.182% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -152.05% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 87.833% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -32.97% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -40.281% |
| GB Sciences, Inc. | 103.44 Thousand USD | -3430.289% |
| Alpha Cognition Inc. | 2.45 Million USD | -48.921% |
| HST Global, Inc. | 1526.00 USD | -239205.505% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -269.628% |
| Halberd Corporation | 10.13 Thousand USD | -35945.82% |
| Enzolytics Inc. | 361.7 Million USD | 98.99% |
| Agentix Corp. | 261.39 Thousand USD | -1297.06% |
| Resverlogix Corp. | 8.11 Million USD | 54.999% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -94.464% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.92% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 92.345% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -470.901% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -15930.034% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 59.194% |
| AVAX Technologies, Inc. | 7.37 Million USD | 50.499% |
| Zenith Capital Corp. | 7410.00 USD | -49182.078% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.892% |
| Ember Therapeutics, Inc. | 184.00 USD | -1984575.0% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1034.784% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1297.209% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -293.53% |
| Kadimastem Ltd | 2.3 Million USD | -58.493% |
| Helix BioMedix, Inc. | 3.02 Million USD | -20.717% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -6296.122% |
| LadRx Corporation | 2.3 Million USD | -58.232% |
| Cell Source, Inc. | 195.17 Thousand USD | -1771.078% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -932.7% |
| NovAccess Global Inc. | 62.24 Thousand USD | -5766.537% |
| Affymax, Inc. | 7.44 Million USD | 50.936% |
| Itoco Inc. | 1.4 Million USD | -160.83% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -3717.6% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -3345.096% |
| Mobile Lads Corp. | 52.00 USD | -7022596.154% |
| CytoDyn Inc. | 11.13 Million USD | 67.207% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -2454.208% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -20323.949% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -847.361% |
| SYBLEU INC | 330.46 Thousand USD | -1005.04% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -791.941% |
| International Stem Cell Corporation | 5.39 Million USD | 32.249% |
| Bioxytran, Inc. | 137.63 Thousand USD | -2553.193% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 75.658% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 77.973% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -4522.534% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -322.331% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 51.419% |
| Neutra Corp. | 2851.00 USD | -127988.46% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 88.731% |
| PureTech Health plc | 693.97 Million USD | 99.474% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 54.755% |
| IXICO plc | 15.84 Million USD | 76.951% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 55.907% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.466% |
| CSL Limited | 38.02 Billion USD | 99.99% |
| Cellectis S.A. | 333.99 Million USD | 98.907% |